# Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

> **NCT02831855** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 694 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** Methotrexate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02831855
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2018-11-19
- **Final completion:** 2018-12-17
- **Target enrollment:** 694 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831855, "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02831855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*